biopharmaceutical company

Sanofi to add Rezurock™ to its transplant portfolio with the acquisition of Kadmon Holdings, Inc.

Adds Rezurock™ (belumosudil) an FDA-approved, first-in-class treatment for adult and pediatric patients 12 years and older with chronic graft-versus-host disease…

3 years ago

Sanofi gains full global rights to a promising antibody for inflammatory disorders with the acquisition of Kymab

(PRESS RELEASE) PARIS/ CAMBRIDGE, 11-Jan-2021 — /EuropaWire/ — French multinational pharmaceutical company Sanofi to acquire Kymab, a clinical-stage biopharmaceutical company…

3 years ago